Cerebras Faces a Double Test: Insider Lockup Expiry Meets a Round of Target Cuts

Cerebras Systems is entering one of the more demanding stretches in its short public life, and it has little to do with Friday's trading tape. The stock climbed 9.8% that day as AI names broadly rebounded from a selloff, a move the Associated Press characterized as an industry-wide counter-swing. But a far more consequential date has now arrived: the lockup period on shares held by major shareholders and insiders is set to expire, opening the door to fresh supply just as Wall Street recalibrates what the company is worth.

That combination — potential new selling pressure meeting an unproven operating story — is why the rebound deserves a cautious reading rather than a victory lap. Whether the original owners actually exercise their newly unlocked right to sell, and how easily the market absorbs any additional shares, now moves to center stage.

Price Targets Come Down, Ratings Stay Put

The analyst community spent the same stretch lowering its sights without losing faith. Wedbush cut its price target to $190 from $290 while reaffirming an Outperform rating, pointing to compressed valuation multiples across the semiconductor and hardware sector and mounting unease over data-center spending. Rosenblatt went further on paper, slashing its target to $170 from $300, yet also stuck with a Buy.

UBS had already moved on November 2, trimming its target to $250 from $330 and keeping its Buy recommendation intact. The pattern across all three houses is consistent: conviction in the business opportunity survives, but the price investors should pay for it does not.

Rosenblatt's revision carries an extra wrinkle. The firm now applies a multiple of 8.0x its estimated revenue per share for fiscal 2028, down from the 14x it had previously placed on its calendar 2028 estimates. Both the multiplier and the reference period have shifted, which reframes the whole debate around a single question: what price are investors willing to pay today for revenue that has not yet arrived?

The OpenAI Contract Cuts Both Ways

The bullish case rests heavily on OpenAI. Rosenblatt ties that relationship to expected revenue of more than $20 billion over three years — a substantial foundation for its Buy rating, provided Cerebras can deliver the contracted work economically.

That "provided" is doing a lot of work. A large revenue promise only creates shareholder value if enough profit remains after the infrastructure is built, which puts margins and execution at the center of the argument. Wedbush, for its part, considers several bear points overdone: doubts about the longevity of the WSE technology, questions over extended depreciation schedules, and skepticism about whether OpenAI will actually use additional Cerebras capacity.

The wider backdrop extends well beyond one company. Falling valuation multiples and anxiety about data-center capex are raising the bar for AI investments generally. Cerebras benefits from the scale of its expected contract volume; it is weighed down by the buildout itself, particularly where permitting and local opposition slow expansion — hurdles CEO Andrew Feldman has publicly flagged.

Ownership, Oracle, and the Case for Patience

Institutional positioning adds another layer. FMR reported on Thursday an economically attributed stake of 17.8%, a reminder of how much hangs on whether large holders stay committed. Their continued allegiance would be a welcome signal — but only if it is grounded in convincing business prospects rather than inertia.

There is a strategic bright spot, too: roughly two weeks ago Cerebras and Oracle announced a collaboration to make Cerebras' high-speed AI inference available on Oracle Cloud Infrastructure. It represents a genuine additional commercial avenue, contingent on the announced plans turning into economically sound execution.

November 12 Is the Real Scorecard

Cerebras has scheduled third-quarter 2026 results for November 12 after the market close. That date, more than any single trading session, will determine whether the more modest valuation framework can hold. Investors will be watching how revenue trajectory and margin outlook fit together — progress will persuade only if it simultaneously demonstrates the economics of growth.

For now, caution has the upper hand. Cerebras still commands credit for its opportunity, backed by three Buy ratings and Rosenblatt's OpenAI revenue expectations, but it is credit extended on stricter terms. The Oracle plans give it a strategic foothold, and the analysts have not walked away. What the stock needs next is evidence that the business can carry those expectations — and a market able to digest whatever supply the expired lockup releases.